John G. Freund, M.D. founded Skyline Ventures, in October 1997 and served as a Managing Director of Skyline until 2023. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management. In November 1995, he co-founded Intuitive Surgical, Inc., and served on its board of directors until March 2000. In 1996, he co-founded Arixa Pharmaceuticals, Inc., and served as its CEO until it was acquired by Pfizer in October 2020. From 1988 to 1994, he held various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, he was at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He serves on the board of directors of Collegium Pharmaceuticals, Inc., Sutro Biopharma, Inc., and SI-Bone, an orthopedic device company. He also serves on the boards of directors of fourteen U.S. registered investment funds managed by affiliates of Capital Group, Inc. He previously served on the boards of directors of Map Pharmaceuticals, Inc., MAKO Surgical Corp., Proteon Therapeutics, Inc., Tetraphase Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., and was Chairman of XenoPort, Inc. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative.
Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar.
What is John Gordon Freund's net worth?
The estimated net worth of John Gordon Freund is at least $1.10 million as of August 8th, 2025. Dr. Freund owns 23,129 shares of Collegium Pharmaceutical stock worth more than $1,097,008 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Freund may own. Learn More about John Gordon Freund's net worth.
How do I contact John Gordon Freund?
Has John Gordon Freund been buying or selling shares of Collegium Pharmaceutical?
John Gordon Freund has not been actively trading shares of Collegium Pharmaceutical within the last three months. Most recently, John Gordon Freund sold 11,659 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.36, for a transaction totalling $400,603.24. Following the completion of the sale, the director now directly owns 23,129 shares of the company's stock, valued at $794,712.44. Learn More on John Gordon Freund's trading history.
Who are Collegium Pharmaceutical's active insiders?
Are insiders buying or selling shares of Collegium Pharmaceutical?
During the last year, insiders at the specialty pharmaceutical company sold shares 14 times. They sold a total of 201,586 shares worth more than $6,745,824.04. The most recent insider tranaction occured on November, 6th when CFO Colleen Tupper sold 30,000 shares worth more than $1,215,900.00. Insiders at Collegium Pharmaceutical own 2.5% of the company.
Learn More about insider trades at Collegium Pharmaceutical. Information on this page was last updated on 11/6/2025.